@ARTICLE{
author={Verschraegen C,Andric Zoran G,Moiseenko FV,Makharadze T,Oleksiienko A,Ruiz EP Yanez,Kim SH,Ahn K,Park TH,Ju HA,Baek EH,Kwon S,Lee SJ,Chang I,Kim SH,Kim HA,Lee E,Ohe Y},
year={2024},
title={3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S1648-S1649},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Lu S,Vynnychenko O,Kulyaba Y,Kuchava V,Ibrahim A,Moiseenko FV,Arslan C,Nguyen DT,Zhang M,Petrovic MD,Cicin I,Bibichadze K,Cil T,Cornfeld M,Tian C,Munteanu M,Sette CVDM,Bondarenko I},
year={2024},
title={POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic nonesmall cell lung cancer (mNSCLC)},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S1633-S1634},
document_type={Meeting Abstract},
}